Common questions about Besivance (FAQ)
Q: How quickly can I expect to see an improvement in my pink eye symptoms after starting Besivance?
A: Official studies on Besivance evaluate the time it takes for the infection to completely clear, which is called clinical resolution. These trials demonstrated high rates of resolution by Day 5 or Day 8 of the study. The product information does not specify the exact time frame for initial symptomatic improvement, but the drug's mechanism of action is immediate upon contact with susceptible bacteria.
Q: Is it normal for Besivance to cause a temporary blurred vision or stinging right after I put the drops in?
A: Regulatory information indicates that blurred vision and eye irritation are reported adverse reactions, occurring in approximately 1% to 2% of patients in clinical trials. While the product label does not explicitly use the term 'stinging,' this sensation is typically covered under the category of 'eye irritation' or 'eye pain.' This sensation may be related to the drops themselves, as blurred vision and eye irritation are listed as common reported adverse reactions.
Q: Is a slight headache a common or expected side effect of Besivance?
A: Yes, regulatory documents indicate that headache is a reported adverse reaction. In clinical trials, headache occurred in approximately 1% to 2% of patients. This incidence means it is one of the more common side effects reported by patients using Besivance.
Q: Can Besivance interact with other eye drops, like lubricating tears or glaucoma medication?
A: Due to the low systemic absorption of Besivance from the eye, systemic drug-drug interactions are generally not expected. While official documents do not list specific timing restrictions for other ophthalmic products, patient information commonly advises that different eye drops should be separated by at least five minutes.
Q: Are there any known drug interactions between Besivance and oral antibiotics or medications?
A: Official regulatory documents indicate that systemic drug-drug interactions are not expected with Besivance. This is because the active ingredient, besifloxacin, has very limited absorption into the body when applied as eye drops. Therefore, the official labeling does not list specific interacting systemic medications or oral antibiotics.
Q: Can Besivance be used in both eyes, even if only one eye seems to be infected?
A: The official dosing instructions specify that one drop should be instilled into the 'affected eye(s).' Decisions on treating both eyes should be determined by a healthcare provider.
Q: Can Besivance treat eye infections caused by viruses or fungi?
A: No. Besivance contains an antibacterial agent, besifloxacin, and is indicated specifically for the treatment of bacterial conjunctivitis. Official patient guidance confirms that the medication will not work for eye infections caused by viruses, fungi, or other non-bacterial pathogens.
Q: Could Besivance eye drops cause a metallic or bad taste in the mouth?
A: This side effect is not listed among the most common adverse reactions in the official Besivance product labeling. A metallic taste is a known, though uncommon, effect of some ophthalmic products that drain into the throat.
Q: Is eye redness a normal side effect of the drop itself, or is it a sign the infection is getting worse?
A: Conjunctival redness is the most frequently reported adverse reaction in clinical trials, occurring in approximately 2% of patients. While it is a known side effect of the drop itself, it is also a primary symptom of the bacterial infection. If eye redness or any symptom worsens after starting therapy, this information should be shared with a healthcare provider.
Q: Why does the Besivance bottle need to be shaken or inverted before each use?
A: Besivance is formulated as an ophthalmic suspension, meaning the active drug ingredient is finely dispersed in a liquid vehicle. The official instructions require the closed bottle to be inverted and shaken once before each use to ensure the active ingredient is properly mixed and evenly distributed in the drop you administer.
Q: What happens if I accidentally touch the tip of the Besivance dropper to my eye?
A: Official patient instructions strongly emphasize the importance of avoiding contamination by not touching the dropper tip to the eye, fingers, or any other surface. If contamination is suspected, information regarding the safe continued use of the bottle should be sought from a healthcare professional.
Q: Can I use Besivance if I am pregnant or breastfeeding?
A: For pregnancy, the official label advises that the medication should generally be used only if the potential benefit justifies the potential risk, as human data is limited. For nursing mothers, caution should be exercised because it is unknown if the drug passes into human milk. Any use of Besivance during pregnancy or while breastfeeding requires a review of the potential benefits and risks.
Q: Does Besivance cause issues with sun exposure or light sensitivity (photophobia)?
A: Light sensitivity, or photophobia, is not listed as a common adverse reaction in the summary of safety data for Besivance. While some antibiotics in the same class (fluoroquinolones) have been associated with sensitivity to sunlight, Besivance is generally not reported to cause this side effect.
Q: Are there any ingredients in Besivance that people with common allergies should be cautious of?
A: Patients with a known hypersensitivity to the active ingredient, besifloxacin, or to other antibiotics in the quinolone class, are advised to avoid its use. Allergies to the inactive ingredients or preservatives in the suspension are a known contraindication for some patients.
Q: How soon after my symptoms clear up can I stop using Besivance?
A: Official instructions emphasize the importance of completing the entire course of therapy as directed by the prescriber. Stopping treatment prematurely, even if symptoms improve, may risk the return of the infection and may contribute to antibiotic resistance.
